Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.
The purpose of this study is to evaluate the efficacy and safety of SL-T10 and GX-I7 or SL-T10, GX-I7 and pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).
Metastatic Castration-resistant Prostate Cancer (mCRPC)
BIOLOGICAL: SL-T10|BIOLOGICAL: GX-I7|BIOLOGICAL: Pembrolizumab
Number of participants with treatment-emergent adverse events (TEAEs), Number of participants with treatment-emergent adverse events (TEAEs), Baseline to 23 weeks|Number of participants with Serious adverse events (SAEs) as assessed by CTCAE v5.0, Number of participants with Serious adverse events (SAEs) as assessed by CTCAE v5.0, Baseline to 48 weeks
PSA response rate, % patients with a reduction in PSA level from baseline by 50% or greater, Baseline to 48 weeks|PSA progression free survival, The interval from the date of randomisation to the date of first evidence of PSA progression or death from any cause, whichever occurred first., Baseline to 48 weeks|Radiographic progression free survival, The interval from the date of disease progression on CT and/or Tc bone scan or death from any cause, whichever occurred first., Baseline to 48 weeks|Change of induced T-cell responses for SL-T10 vaccine, Vaccine-induced T-cell responses assessed by immunoassays in peripheral blood, Baseline to 48 weeks
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of SL-T10, GX-I7, and pembrolizumab in combination in patients with metastatic castration-resistant prostate cancer (mCRPC).